Hixon Zuercher LLC Raises Stake in Edwards Lifesciences Co. (NYSE:EW)

Hixon Zuercher LLC grew its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 27,617 shares of the medical research company’s stock after acquiring an additional 312 shares during the quarter. Hixon Zuercher LLC’s holdings in Edwards Lifesciences were worth $1,822,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Crewe Advisors LLC purchased a new stake in Edwards Lifesciences during the 1st quarter valued at about $28,000. First Community Trust NA bought a new position in shares of Edwards Lifesciences in the second quarter worth approximately $29,000. Webster Bank N. A. bought a new position in shares of Edwards Lifesciences in the second quarter worth approximately $39,000. Peoples Bank KS purchased a new position in shares of Edwards Lifesciences in the third quarter worth $40,000. Finally, Versant Capital Management Inc raised its holdings in Edwards Lifesciences by 206.3% during the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after buying an additional 326 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Up 0.3 %

Shares of NYSE:EW opened at $66.69 on Wednesday. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. The stock has a fifty day simple moving average of $67.81 and a two-hundred day simple moving average of $77.26. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The stock has a market capitalization of $40.17 billion, a price-to-earnings ratio of 9.62, a PEG ratio of 3.80 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 22.56% and a net margin of 70.82%. The company’s revenue was up 8.9% on a year-over-year basis. During the same period last year, the company earned $0.59 earnings per share. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Barclays decreased their price objective on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Citigroup lowered their price target on Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research report on Tuesday, October 1st. Evercore ISI cut their price objective on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. UBS Group decreased their target price on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a report on Tuesday, September 10th. Finally, TD Cowen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their price target for the company from $100.00 to $70.00 in a report on Thursday, July 25th. Seventeen equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $75.67.

Insiders Place Their Bets

In related news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,101,530.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,250 shares of company stock valued at $2,746,988. Insiders own 1.27% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.